No surprise: AbbVie turns cold shoulder to a messy rheumatoid arthritis partnership with Ablynx
AbbVie is punting yet another high-profile rheumatoid arthritis development partnership. The pharma outfit is taking a pass on Ablynx’s Phase III-ready drug vobarilizumab and shrugging …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.